Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Stock analysts at HC Wainwright increased their FY2026 earnings per share (EPS) estimates for shares of Cardiff Oncology in a report issued on Monday, November 16th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($0.55) for the year, up from their prior forecast of ($0.56). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Cardiff Oncology's current full-year earnings is ($0.58) per share. HC Wainwright also issued estimates for Cardiff Oncology's Q1 2027 earnings at ($0.08) EPS, Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.07) EPS and FY2027 earnings at ($0.29) EPS.
Other analysts also recently issued reports about the stock. Wall Street Zen raised shares of Cardiff Oncology from a "strong sell" rating to a "sell" rating in a research report on Saturday, September 5th. Weiss Ratings raised shares of Cardiff Oncology from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, November 9th. Finally, William Blair cut shares of Cardiff Oncology from an "outperform" rating to a "market perform" rating in a report on Tuesday, August 11th. Three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $7.50.
Read Our Latest Stock Report on Cardiff Oncology
Cardiff Oncology Stock Down 0.2%
CRDF opened at $0.85 on Wednesday. The stock has a 50-day moving average price of $1.03 and a 200-day moving average price of $1.34. Cardiff Oncology has a 1 year low of $0.71 and a 1 year high of $3.31.
Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.02. Cardiff Oncology had a negative return on equity of 111.80% and a negative net margin of 6,736.49%. The business had revenue of $0.17 million during the quarter, compared to analysts' expectations of $0.08 million.
Institutional Trading of Cardiff Oncology
Institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. bought a new stake in Cardiff Oncology in the 2nd quarter worth about $1,265,000. GoalVest Advisory LLC purchased a new position in Cardiff Oncology in the 3rd quarter worth about $832,000. Flputnam Investment Management Co. purchased a new position in Cardiff Oncology in the 2nd quarter worth about $322,000. X Square Capital LLC bought a new position in Cardiff Oncology during the 2nd quarter valued at about $267,000. Finally, GSA Capital Partners LLP bought a new position in Cardiff Oncology during the 2nd quarter valued at about $225,000. Institutional investors own 16.29% of the company's stock.
Cardiff Oncology Company Profile
(
Get Free Report)
Cardiff Oncology is a clinical-stage biotechnology company focused on developing cancer treatments. Its lead drug candidate, onvansertib, is an oral, selective inhibitor of polo-like kinase 1 (PLK1), a protein involved in cell division that the company is investigating as a target in cancer therapy. The company is studying onvansertib in combination with existing treatments for several cancers, including metastatic colorectal cancer and acute myeloid leukemia. These programs remain in clinical development, and the candidate is not an approved treatment.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cardiff Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiff Oncology wasn't on the list.
While Cardiff Oncology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.